Department of Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences and Medicine, Sendai, Japan.
Clin Exp Hypertens. 2011;33(7):427-36. doi: 10.3109/10641963.2010.531844. Epub 2011 Jul 21.
Low-dose (25 mg) or very low-dose (12.5 mg) spironolactone were added among 86 uncontrolled hypertensive patients who were undergoing monotherapy with calcium channel blockers (CCBs), angiotensin-converting enzyme inhibitors (ACEIs), or angiotensin AT1-receptor blockers (ARBs). Morning home systolic/diastolic blood pressure (BP) reduction was similar among the CCB (n = 30, -8.2/-2.6 mmHg), ACEI (n = 22, -13.0/-4.7 mmHg), and ARB (n = 34, -11.5/-5.1 mmHg) groups. An increase in serum potassium correlated positively with the decline in morning systolic BP. Even very low-dose (12.5 mg) spironolactone is clinically effective, although serum potassium should be carefully monitored.
在 86 名正在接受钙通道阻滞剂（CCB）、血管紧张素转换酶抑制剂（ACEI）或血管紧张素 AT1 受体阻滞剂（ARB）单药治疗的未控制高血压患者中，添加了低剂量（25 毫克）或超低剂量（12.5 毫克）螺内酯。CCB（n=30，-8.2/-2.6 mmHg）、ACEI（n=22，-13.0/-4.7 mmHg）和 ARB（n=34，-11.5/-5.1 mmHg）组患者的清晨家庭收缩压/舒张压（BP）降低情况相似。血清钾的升高与清晨收缩压的下降呈正相关。即使是非常低剂量（12.5 毫克）的螺内酯也具有临床疗效，但应密切监测血清钾。
